In a report released yesterday, Daniele Alibrandi from Stifel Nicolaus reiterated a Buy rating on PharmaNutra SpA (PHN – Research Report), with a price target of €88.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Daniele Alibrandi has given his Buy rating due to a combination of factors that highlight PharmaNutra SpA’s promising growth prospects. The company has set ambitious targets for its key projects in the US and China, surpassing both the firm’s and market expectations. These targets are supported by a robust R&D pipeline, which includes a diverse range of innovative products across various fields such as pediatrics, orthopedics, and sports nutrition.
PharmaNutra’s strategic initiatives, including the establishment of a new headquarters in Miami and the development of multiple distribution channels, are expected to drive significant revenue growth. The company’s efforts in digital marketing and e-commerce, along with its collaborations with hospital groups, are anticipated to enhance its market presence. With projected sales growth in both the US and Chinese markets, PharmaNutra is well-positioned to achieve substantial financial gains, justifying the Buy rating.
In another report released on March 17, Intermonte also maintained a Buy rating on the stock with a €87.00 price target.